CDSCO Publishes Alert For Failed Samples Of September 2024

New Delhi:  The CDSCO has published three lists of products declared as Not of Standard Quality (NSQ) and Spurious for September 2024. All these three lists were published on October 24, 2024.

These lists are as follows:

  1. Dugs analyzed by CDSCO/ central laboratories,
  2. Drugs that have been analyzed by state laboratories, and
  3. Drugs, Medical Devices, Vaccine and Cosmetics declared as Spurious/Adulterated/Misbranded

Not of Standard Quality (NSQ) drugs refer to drugs that fail to meet quality standards or specifications. The term ‘standards of quality’ is defined in the Drugs & Cosmetics Act, 1940, to mean that the drug complies with the standards set out in the Second Schedule of the said Act.

Central Laboratories NSQ List of drugs/ products

The NSQ drug list for central CDSCO laboratories specifies a total of 49 drugs that were detected to be deficient.

Out of the 49 NSQ drugs from CDSCO/Central Laboratories, 19 were reported by Central Drug Laboratory (CDL), Kolkata; 9 were reported by Regional Drugs Testing Laboratory (RDTL), Chandigarh; 15 were reported by RDTL, Guwahati; 5 were reported by Central Drugs Testing Laboratory (CDTL), Mumbai and 1 was reported by CDTL, Hyderabad.

State Laboratories NSQ List of drugs/ products

The NSQ drug list specifies a total of 18 drugs that were detected to be deficient by the state laboratories. All of these 18 drugs were declared to be not of standard quality.

Out of these 18 drugs, 15 were reported by Drugs Testing Laboratory Thiruvananthapuram and 3 was reported by Jammu and Kashmir.

It is pertinent to note that CDSCO did not receive NSQ data as per Format & in EXCEL SHEET from State Drugs Licensing Authorities of Karnataka (PDF format), Thiruvanthapuram (Excel format), and Jammu Kashmir (Excel Format) for the Month of September, 2024.

However, the State Drugs Licensing Authorities of Arunachal Pradesh, Assam, Bihar, Chhattisgarh, Goa, Gujarat, Haryana, Himachal Pradesh, Manipur, Rajasthan, Meghalaya, Mizoram, Nagaland, Odisha, Punjab, Sikkim, Tamil Nadu, Pondicherry, Telangana, Delhi, Uttarakhand, West Bengal, Andaman & Nicobar, Dadar and Nagar Haveli; Daman and Diu, Lakshadweep have not submitted any data in respect of the Not of Standard Quality (NSQ) Alert for the Month of August, 2024.

Drugs, Medical Devices, Vaccine and Cosmetics declared as Spurious/Adulterated/Misbranded

This list specifies a total of 4 drugs. All 4 drugs were detected to be spurious by the actual manufacturers of the claimed drugs. The Drugs Inspector, Odisha; Drugs Inspector, EZ, Kolkata; Drugs Inspector, Bihar; and Drugs Inspector, NZ, Ghaziabad were responsible for drawing these drugs.

All of these drugs are subject to ongoing investigation.

Related Posts

Remedium Lifecare ‘s Breakthrough: A New Era in Pharma

Mumbai: Remedium Lifecare Limited, a pivotal player in India’s pharmaceutical industry, has clinched a noteworthy contract with a UK-based pharmaceutical distribution firm, promising to amplify its stature in the global…

  • Pharma
  • February 18, 2025
  • 102 views
Bihar man booked in Haryana for online sale of abortion pills

The health department authorities in Yamunanagar and Gurugram districts of Haryana have lodged two first information reports (FIRs) against a Bihar-based illegal online distributor of medical abortion kits, a Schedule-H…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Remedium Lifecare ‘s Breakthrough: A New Era in Pharma

Remedium Lifecare ‘s Breakthrough: A New Era in Pharma

Bihar man booked in Haryana for online sale of abortion pills

Bihar man booked in Haryana for online sale of abortion pills

FDA busts spurious drug racket; medicines worth Rs 12.47 seized

FDA busts spurious drug racket; medicines worth Rs 12.47 seized

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance